We Think That There Are More Issues For Jiangsu Canopus Wisdom Medical TechnologyLtd (SZSE:301290) Than Just Sluggish Earnings
We Think That There Are More Issues For Jiangsu Canopus Wisdom Medical TechnologyLtd (SZSE:301290) Than Just Sluggish Earnings
Jiangsu Canopus Wisdom Medical Technology Co.,Ltd.'s (SZSE:301290) recent weak earnings report didn't cause a big stock movement. We think that investors are worried about some weaknesses underlying the earnings.
江苏飞凡智慧医疗科技有限公司(SZSE:301290)最近的疲弱收益报告没有引起股票大动。我们认为投资者担心收益背后的一些弱点。
The Impact Of Unusual Items On Profit
除了稀释之外,还应该注意的是,万集科技在过去12个月中因不寻常项目获得了价值人民币3.5万元的利润。虽然我们希望看到利润增加,但当这些不寻常项目对利润做出重大贡献时,我们会更加谨慎。我们对全球大部分上市公司的数据进行了分析,发现不寻常项目往往是一次性的。这正如我们所期望的那样,因为这些提升被描述为"不寻常"。相对于其利润而言,万集科技在2021年12月前的不寻常项目贡献大。因此,我们可以推断出,这些不寻常项目正在使其财务利润显著增强。
Importantly, our data indicates that Jiangsu Canopus Wisdom Medical TechnologyLtd's profit received a boost of CN¥5.8m in unusual items, over the last year. While we like to see profit increases, we tend to be a little more cautious when unusual items have made a big contribution. When we analysed the vast majority of listed companies worldwide, we found that significant unusual items are often not repeated. And that's as you'd expect, given these boosts are described as 'unusual'. If Jiangsu Canopus Wisdom Medical TechnologyLtd doesn't see that contribution repeat, then all else being equal we'd expect its profit to drop over the current year.
重要的是,我们的数据显示,江苏飞凡智慧医疗科技有限公司的利润在过去一年中因为飞凡项目增加了580万人民币。虽然我们喜欢看到利润增加,但当飞凡项目对利润有重大贡献时,我们会更加谨慎。当我们分析全球绝大多数上市公司时,我们发现重大的飞凡项目通常不会重复出现。这是可以预期的,因为这些提升被描述为“飞凡”。如果江苏飞凡智慧医疗科技有限公司不再看到这种贡献的重复,那么在其他条件不变的情况下,我们预计其利润将在当前年份下降。
Note: we always recommend investors check balance sheet strength. Click here to be taken to our balance sheet analysis of Jiangsu Canopus Wisdom Medical TechnologyLtd.
注意:我们始终建议投资者检查资产负债表健康状况。点击此处以查看我们对江苏飞凡智慧医疗科技有限公司资产负债表的分析。
Our Take On Jiangsu Canopus Wisdom Medical TechnologyLtd's Profit Performance
我们对江苏飞凡智慧医疗科技有限公司的利润表现的看法
We'd posit that Jiangsu Canopus Wisdom Medical TechnologyLtd's statutory earnings aren't a clean read on ongoing productivity, due to the large unusual item. Because of this, we think that it may be that Jiangsu Canopus Wisdom Medical TechnologyLtd's statutory profits are better than its underlying earnings power. Sadly, its EPS was down over the last twelve months. Of course, we've only just scratched the surface when it comes to analysing its earnings; one could also consider margins, forecast growth, and return on investment, among other factors. So while earnings quality is important, it's equally important to consider the risks facing Jiangsu Canopus Wisdom Medical TechnologyLtd at this point in time. For example - Jiangsu Canopus Wisdom Medical TechnologyLtd has 1 warning sign we think you should be aware of.
我们认为,江苏飞凡创智医疗科技有限公司的法定收益并不能准确反映其持续盈利能力,因为存在大额飞凡项。因此,我们认为江苏飞凡创智医疗科技有限公司的法定利润可能比其潜在盈利能力更好。不幸的是,其每股收益在过去12个月内下降了。当然,在分析其收益时,我们只是触及到了表面,还可以考虑利润率、预测增长和投资回报率等其他因素。因此,尽管收益质量很重要,但同样重要的是要考虑江苏飞凡创智医疗科技有限公司目前面临的风险。例如,我们认为江苏飞凡创智医疗科技有限公司存在1个警示信号,您应该注意。
This note has only looked at a single factor that sheds light on the nature of Jiangsu Canopus Wisdom Medical TechnologyLtd's profit. But there is always more to discover if you are capable of focussing your mind on minutiae. For example, many people consider a high return on equity as an indication of favorable business economics, while others like to 'follow the money' and search out stocks that insiders are buying. So you may wish to see this free collection of companies boasting high return on equity, or this list of stocks with high insider ownership.
本文只关注了一个可以揭示江苏飞凡创智医疗科技有限公司利润性质的因素。但如果您能够将注意力集中在细枝末节上,还有更多可以发现的内容。例如,许多人认为高净资产回报率是良好经营经济状况的指标,而其他人则喜欢“追踪资金”,寻找内部人士正在买入的股票。因此,您可能希望查看这个免费的高净资产回报率公司收藏集,或者这个高内部持股的股票清单。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
对本文有任何反馈?对内容有任何疑虑?请直接与我们联系。或者,发送电子邮件至editorial-team@simplywallst.com。
这篇文章是Simply Wall St的一般性文章。我们根据历史数据和分析师预测提供评论,只使用公正的方法论,我们的文章并不意味着提供任何金融建议。文章不构成买卖任何股票的建议,也不考虑您的目标或您的财务状况。我们的目标是带给您基本数据驱动的长期关注分析。请注意,我们的分析可能不考虑最新的价格敏感公司公告或定性材料。Simply Wall St没有任何股票头寸。